工业大麻活性成分及其生理功能研究进展

doi:10.19586/j.2095-2341.2023.0003

生物技术进展 ›› 2023, Vol. 13 ›› Issue (3): 329-338.DOI: 10.19586/j.2095-2341.2023.0003

工业大麻活性成分及其生理功能研究进展

姚圣泓¹(), 祝纤纤¹, 朱至锴¹, 仝涛¹^,²^,³()

^1.中国农业大学食品科学与营养工程学院，精准营养与食品质量重点实验室，教育部功能乳品重点实验室，北京 100083
^2.农业农村部转基因生物安全评价重点实验室（食品安全），北京 100083
^3.食品质量与安全北京实验室，北京 100083

收稿日期:2023-01-11 接受日期:2023-02-27 出版日期:2023-05-25 发布日期:2023-06-12
通讯作者: 仝涛
作者简介:姚圣泓 E-mail: 2020306010413@cau.edu.cn；
基金资助:
山东省自然科学基金项目(ZR2021QC118);北京市自然科学基金项目(7222249);中国农业大学2115人才工程资助项目

Research Progress on Active Components and Their Physiological Functions of Industrial Hemp

Shenghong YAO¹(), Qianqian ZHU¹, Zhikai ZHU¹, Tao TONG¹^,²^,³()

^1.School of Food Science and Nutrition Engineering，Key Laboratory of Precision Nutrition and Food Quality，Key Laboratory of Functional Dairy Products，Ministry of Education，China Agricultural University，Beijing 100083，China
^2.Key Laboratory of Safety Evaluation of Genetically Modified Organisms （Food Safety），Ministry of Agriculture and Rural Affairs，Beijing 100083，China
^3.Beijing Laboratory of Food Quality and Safety，Beijing 100083，China

Received:2023-01-11 Accepted:2023-02-27 Online:2023-05-25 Published:2023-06-12
Contact: Tao TONG

摘要/Abstract

摘要：

工业大麻是一种四氢大麻酚含量小于0.3%的大麻，含有多种生物活性成分，包括大麻素类、类黄酮类及萜烯类化合物。研究表明，工业大麻中的大麻素类化合物包括大麻二酚、四氢大麻酚和大麻萜酚等，类黄酮类化合物包括山柰酚和芹菜素等，萜烯类化合物包括单萜和倍半萜等，这些活性物质有多种生理功能。总结了近几年来工业大麻的抗癌、抗炎、抗氧化、镇痛、治疗癫痫及保护肝脏等多种生理功能的研究进展，以期为工业大麻在医药、化妆品等领域的应用提供一定理论依据。

关键词: 工业大麻, 大麻素, 类黄酮, 萜烯类化合物

Abstract:

Industrial hemp is a type of Cannabis sativa with less than 0.3% tetrahydrocannabinol. Industrial hemp contains several bioactive components， including cannabinoids， flavonoids， and terpenes. Studies have shown that cannabinoids include cannabidiol， tetrahydrocannabinol， and cannabigerol； flavonoids include kaempferol and apigenin； terpenes include monoterpenes and sesquiterpenes. These active substances have multiple physiological functions. This review summarized the recent progress of industrial hemp， including anticancer， anti-inflammatory， antioxidant， analgesic， antiepileptic and liver protection， aiming to provide theoretical basis for the application of industrial hemp in medicine and cosmetics.

Key words: industrial hemp, cannabinoids, flavonoids, terpenes

中图分类号:

S563.3

姚圣泓, 祝纤纤, 朱至锴, 仝涛. 工业大麻活性成分及其生理功能研究进展[J]. 生物技术进展, 2023, 13(3): 329-338.

Shenghong YAO, Qianqian ZHU, Zhikai ZHU, Tao TONG. Research Progress on Active Components and Their Physiological Functions of Industrial Hemp[J]. Current Biotechnology, 2023, 13(3): 329-338.

图/表 2

参考文献 84

1	李秋实,孟莹,陈士林.药用大麻种质资源分类与研究策略[J].中国中药杂志,2019,44(20):4309-4316.
2	RADWAN M M, CHANDRA S, GUL S, et al.. Cannabinoids, phenolics, terpenes and alkaloids of Cannabis [J/OL]. Molecules, 2021, 26(9): 2774[2022-09-15]. .
3	BAUTISTA J L, YU S, TIAN L. Flavonoids in Cannabis sativa: biosynthesis, bioactivities, and biotechnology[J]. ACS Omega, 2021, 6(8): 5119-5123.
4	SOMMANO S R, CHITTASUPHO C, RUKSIRIWANICH W, et al.. The Cannabis terpenes[J/OL]. Molecules, 2020, 25(24): 5792[2022-10-28]. .
5	BONINI S A, PREMOLI M, TAMBARO S, et al.. Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history[J]. J. Ethnopharmacol., 2018, 227: 300-315.
6	MARTINS A M, GOMES A L, VILAS B I, et al.. Cannabis-based products for the treatment of skin inflammatory diseases: a timely review[J/OL]. Pharmaceuticals, 2022, 15(2): 210[2022-10-07]. .
7	DARIS B, TANCER V M, KNEZ Z, et al.. Cannabinoids in cancer treatment: therapeutic potential and legislation[J]. Bosn. J. Basic Med. Sci., 2019, 19(1): 14-23.
8	赵浩含,陈继康,熊和平.中国工业大麻种业创新发展策略研究[J].农业现代化研究,2020,41(5):765-771.
9	曹焜,王晓楠,孙宇峰,等.中国工业大麻品种选育研究进展[J].中国麻业科学,2019,41(4):187-192.
10	刘诗博,吴昊,洪焦,等.炎症-肿瘤转化在眼部相关疾病中的研究进展[J].生物技术进展,2020,10(3):234-241.
11	SUNG H, FERLAY J, SIEGEL R L, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J. Clin., 2021, 71(3): 209-249.
12	SATIJA A, AHMED S M, GUPTA R, et al.. Breast cancer pain management-a review of current & novel therapies[J]. Indian J. Med. Res., 2014, 139(2): 216-225.
13	SULTAN A S, MARIE M A, SHEWEITA S A. Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines[J]. Breast, 2018, 41: 34-41.
14	SCHOEMAN R, BEUKES N, FROST C. Cannabinoid combination induces cytoplasmic vacuolation in MCF-7 breast cancer cells[J/OL]. Molecules, 2020, 25(20): 4682[2021-11-23]. .
15	AMARAL C, TROUILLE F M, ALMEIDA C F, et al.. Unveiling the mechanism of action behind the anti-cancer properties of cannabinoids in ER⁺ breast cancer cells: impact on aromatase and steroid receptors[J/OL]. J. Steroid Biochem. Mol. Biol., 2021, 210: 105876[2022-08-10]. .
16	STANFORD J L, FENG Z, HAMILTON A S, et al.. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study[J]. JAMA, 2000, 283(3): 354-360.
17	CHAI E Z, SIVEEN K S, SHANMUGAM M K, et al.. Analysis of the intricate relationship between chronic inflammation and cancer[J]. Biochem. J., 2015, 468(1): 1-15.
18	SHARMA M, HUDSON J B, ADOMAT H, et al.. In vitro anticancer activity of plant-derived Cannabidiol on prostate cancer cell lines[J]. Pharmacol. Pharm., 2014, 5(8): 806-820.
19	DE-PETROCELLIS L, LIGRESTI A, SCHIANO M A, et al.. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms[J]. Br. J. Pharmacol., 2013, 168(1): 79-102.
20	RENI M, MAZZA E, ZANON S, et al.. Central nervous system gliomas[J]. Crit. Rev. Oncol. Hemat., 2017, 113: 213-234.
21	NABISSI M, MORELLI M B, AMANTINI C, et al.. Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner[J]. Int. J. Cancer, 2015, 137(8): 1855-1869.
22	SOROCEANU L, SINGER E, DIGHE P, et al.. Cannabidiol inhibits RAD51 and sensitizes glioblastoma to temozolomide in multiple orthotopic tumor models[J/OL]. Neurooncol. Adv., 2022, 4(1): c19[2022-08-18]. .
23	SINGER E, JUDKINS J, SALOMONIS N, et al.. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma[J/OL]. Cell Death Dis., 2015, 6: e1601[2022-08-17]. .
24	KOSGODAGE U S, UYSAL-ONGANER P, MACLATCHY A, et al.. Cannabidiol affects extracellular vesicle release, miR21 and miR126, and reduces prohibitin protein in glioblastoma multiforme cells[J]. Transl. Oncol., 2019, 12(3): 513-522.
25	SANDRU A, VOINEA S, PANAITESCU E, et al.. Survival rates of patients with metastatic malignant melanoma[J]. J. Med. Life, 2014, 7(4): 572-576.
26	ARMSTRONG J L, HILL D S, MCKEE C S, et al.. Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death[J]. J. Invest. Dermatol., 2015, 135(6): 1629-1637.
27	GLODDE N, JAKOBS M, BALD T, et al.. Differential role of cannabinoids in the pathogenesis of skin cancer[J]. Life Sci., 2015, 138: 35-40.
28	SIMMERMAN E, QIN X, YU J C, et al.. Cannabinoids as a potential new and novel treatment for melanoma: a pilot study in a murine model[J]. J. Surg. Res., 2019, 235: 210-215.
29	HENSHAW F R, DEWSBURY L S, LIM C K, et al.. The effects of Cannabinoids on pro- and anti-inflammatory cytokines: a systematic review of in vivo studies[J]. Cannabis Cannabinoid Res., 2021, 6(3): 177-195.
30	ALETAHA D, SMOLEN J S. Diagnosis and management of rheumatoid arthritis: a review[J]. JAMA, 2018, 320(13): 1360-1372.
31	HAMMELL D C, ZHANG L P, MA F, et al.. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis[J]. Eur. J. Pain, 2016, 20(6): 936-948.
32	LOWIN T, TINGTING R, ZURMAHR J, et al.. Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts[J/OL]. Cell Death Dis., 2020, 11(8): 714[2022-04-12]. .
33	LOBENTANZ I S, ASENBAUM S, VASS K, et al.. Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality[J]. Acta Neurol. Scand., 2004, 110(1): 6-13.
34	DOBSON R, GIOVANNONI G. Multiple sclerosis-a review[J]. Eur. J. Neurol., 2019, 26(1): 27-40.
35	AL-GHEZI Z Z, MIRANDA K, NAGARKATTI M, et al.. Combination of Cannabinoids, delta9-tetrahydrocannabinol and Cannabidiol, ameliorates experimental multiple sclerosis by suppressing neuroinflammation through regulation of miRNA-mediated signaling pathways[J/OL]. Front. Immunol., 2019, 10: 1921[2022-05-23]. .
36	ELLIOTT D M, SINGH N, NAGARKATTI M, et al.. Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells[J/OL]. Front. Immunol., 2018, 9: 1782[2022-05-25]. .
37	FELIU A, MORENO-MARTET M, MECHA M, et al.. A sativex(R)-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis[J]. Br. J. Pharmacol., 2015, 172(14): 3579-3595.
38	SAMUELS D V, ROSENTHAL R, LIN R, et al.. Acne vulgaris and risk of depression and anxiety: a meta-analytic review[J]. J. Am. Acad. Dermatol., 2020, 83(2): 532-541.
39	OLÁH A, TÓTH B I, BORBÍRÓ I, et al.. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes[J]. J. Clin. Invest., 2014, 124(9): 3713-3724.
40	OLÁH A, MARKOVICS A, SZABÓ-PAPP J, et al.. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment[J]. Exp. Dermatol., 2016, 25(9): 701-707.
41	GAFFAL E, CRON M, GLODDE N, et al.. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors[J]. Allergy, 2013, 68(8): 994-1000.
42	BAUMJOHANN D, ANSEL K M. MicroRNA-mediated regulation of T helper cell differentiation and plasticity[J]. Nat. Rev. Immunol., 2013, 13(9): 666-678.
43	SIDO J M, JACKSON A R, NAGARKATTI P S, et al.. Marijuana-derived Δ‍-9-tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation[J]. J. Mol. Med., 2016, 94(9): 1039-1051.
44	PETROSINO S, VERDE R, VAIA M, et al.. Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis[J]. J. Pharmacol. Exp. Ther., 2018, 365(3): 652-663.
45	COTO-SEGURA P, EIRIS-SALVADO N, GONZALEZ-LARA L, et al.. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis[J]. Br. J. Dermatol., 2013, 169(4): 783-793.
46	VINCENZI C, TOSTI A. Efficacy and tolerability of a shampoo containing broad-spectrum cannabidiol in the treatment of scalp inflammation in patients with mild to moderate scalp psoriasis or seborrheic dermatitis[J]. Skin Appendage Disord., 2020, 6(6): 355-361.
47	LEKHRAM C, GEORGE A. Method to treat psoriasis: US2019060250(A1)[P]. 2019-02-28.
48	MONEY S, GARBER B. Management of cancer pain[J]. Cur. Emerg. Hospital Med. Rep., 2018, 6(4): 141-146.
49	ZHANG J M, AN J. Cytokines, inflammation, and pain[J]. Int. Anesthesio.l Clin., 2007, 45(2): 27-37.
50	STAROWICZ K, FINN D P. Chapter thirteen-cannabinoids and pain: sites and mechanisms of action[M]//KENDALL D, ALEXANDER S P H. Advances in pharmacology. Massachusetts: Academic Press, 2017: 437-475.
51	ABRAHAM A D, LEUNG E J Y, WONG B A, et al.. Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain[J]. Neuropsychopharmacol. (New York), 2020, 45(7): 1105-1114.
52	ELLIS L D, BERRUE F, MORASH M, et al.. Comparison of cannabinoids with known analgesics using a novel high throughput zebrafish larval model of nociception[J]. Behav. Brain Res., 2018, 337: 151-159.
53	WILSEY B L, DEUTSCH R, SAMARA E, et al.. A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis[J]. J. Pain Res., 2016, 9: 587-598.
54	FITZCHARLES M A, BAERWALD C, ABLIN J, et al.. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials[J]. Schmerz, 2016, 30(1): 47-61.
55	严江涛.大麻二酚抗氧化活性研究及不同环境差异下转录组分析[D]. 北京: 中国农业科学院,2020.
56	CASARES L, GARCÍA V, GARRIDO-RODRÍGUEZ M, et al.. Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1[J/OL]. Redox Biol., 2020, 28: 101321[2021-10-12]. .
57	SONG P, LIU Y, YU X, et al.. Prevalence of epilepsy in China between 1990 and 2015: a systematic review and meta-analysis[J/OL]. J. Glob. Health, 2017, 7(2): 20706[2022-08-01]. .
58	ROSENBERG E C, TSIEN R W, WHALLEY B J, et al.. Cannabinoids and epilepsy[J]. Neurotherapeutics, 2015, 12(4): 747-768.
59	HOSSEINZADEH M, NIKSERESHT S, KHODAGHOLI F, et al.. Cannabidiol post-treatment alleviates rat epileptic-related behaviors and activates hippocampal cell autophagy pathway along with antioxidant defense in chronic phase of pilocarpine-induced seizure[J]. J. Mol. Neurosci., 2016, 58(4): 432-440.
60	PATRA P H, BARKER-HALISKI M, WHITE H S, et al.. Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models[J]. Epilepsia, 2019, 60(2): 303-314.
61	HILL A J, MERCIER M S, HILL T D, et al.. Cannabidivarin is anticonvulsant in mouse and rat[J]. Br. J. Pharmacol., 2012, 167(8): 1629-1642.
62	HUIZENGA M N, SEPULVEDA-RODRIGUEZ A, FORCELLI P A. Preclinical safety and efficacy of cannabidivarin for early life seizures[J]. Neuropharmacology, 2019, 148: 189-198.
63	MORANO A, FANELLA M, ALBINI M, et al.. Cannabinoids in the treatment of epilepsy: current status and future prospects[J]. Neuropsychiatr. Dis. Treat, 2020, 16: 381-396.
64	DIAS M C, PINTO D, SILVA A. Plant flavonoids: chemical characteristics and biological activity[J/OL]. Molecules, 2021, 26(17): 5377[2022-09-15]. .
65	KUMAR P, MAHATO D K, KAMLE M, et al.. Pharmacological properties, therapeutic potential, and legal status of Cannabis sativa L.: an overview[J]. Phytother. Res., 2021, 35(11): 6010-6029.
66	田爱莹.汉麻叶活性成分的提取分离及其抗氧化活性研究[D].天津: 天津科技大学,2015.
67	刘毅.工业大麻叶的成分分析及生物活性初步研究[D].北京: 中国农业科学院,2020.
68	ZHU L, XUE L. Kaempferol suppresses proliferation and induces cell cycle arrest, apoptosis, and DNA damage in breast cancer cells[J]. Oncol. Res., 2019, 27(6): 629-634.
69	RIAHI-CHEBBI I, SOUID S, OTHMAN H, et al.. The phenolic compound kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells[J/OL]. Sci. Rep., 2019, 9(1): 195[2022-09-20]. .
70	LEE J, KIM J H. Kaempferol inhibits pancreatic cancer cell growth and migration through the blockade of EGFR-related pathway in vitro[J/OL]. PLoS ONE, 2016, 11(5): e155264[2022-09-22]. .
71	TONG J, SHEN Y, ZHANG Z, et al.. Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-kB/snail signaling pathway[J/OL]. Biosci. Rep., 2019, 39(5): BSR20190452[2022-09-25]. .
72	NELSON N, SZEKERES K, ICLOZAN C, et al.. Apigenin: selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer[J/OL]. PLoS ONE, 2017, 12(2): e170197[2022-09-28]. .
73	GILARDINI MONTANI M S, CECERE N, GRANATO M, et al.. Mutant p53, stabilized by its interplay with HSP90, activates a positive feed-back loop between NRF2 and p62 that induces chemo-resistance to apigenin in pancreatic cancer cells[J/OL]. Cancers, 2019, 11(5): 703[2022-09-28]. .
74	KOYAMA Y, BRENNER D A. Liver inflammation and fibrosis[J]. J. Clin. Invest., 2017, 127(1): 55-64.
75	WANG M, SUN J, JIANG Z, et al.. Hepatoprotective effect of kaempferol against alcoholic liver injury in mice[J]. Am. J. Chin. Med., 2015, 43(2): 241-254.
76	ZHOU B, JIANG Z, LI X, et al.. Kaempferol's protective effect on ethanol-induced mouse primary hepatocytes injury involved in the synchronous inhibition of SP1, Hsp70 and CYP2E1[J]. Am. J. Chin. Med., 2018, 46(5): 1093-1110.
77	TOMKO A M, WHYNOT E G, ELLIS L D, et al.. Anti-cancer potential of cannabinoids, terpenes, and flavonoids present in Cannabis[J/OL]. Cancers (Basel), 2020, 12(7): 1985[2022-10-30]. .
78	SOBRAL M V, XAVIER A L, LIMA T C, et al.. Antitumor activity of monoterpenes found in essential oils[J/OL]. Scientif.World J., 2014, 2014: 953451[2022-10-30]. .
79	YU X, LIN H, WANG Y, et al.. D-limonene exhibits antitumor activity by inducing autophagy and apoptosis in lung cancer[J]. Onco. Targets Ther., 2018, 11: 1833-1847.
80	HAFIDH R R, HUSSEIN S Z, MALALLAH M Q, et al.. A high-throughput quantitative expression analysis of cancer-related genes in human HepG2 cells in response to limonene, a potential anticancer agent[J]. Curr. Cancer Drug Tar., 2018, 18(8): 807-815.
81	LUCAS C J, GALETTIS P, SCHNEIDER J. The pharmacokinetics and the pharmacodynamics of cannabinoids[J]. Br. J. Clin. Pharmacol., 2018, 84(11): 2477-2482.
82	LIU Z, MARTIN J H. Gaps in predicting clinical doses for cannabinoids therapy: overview of issues for pharmacokinetics and pharmacodynamics modelling[J]. Br. J. Clin. Pharmacol., 2018, 84(11): 2483-2487.
83	JHAWAR N, SCHOENBERG E, WANG J V, et al.. The growing trend of cannabidiol in skincare products[J]. Clin.Dermatol., 2019, 37(3): 279-281.
84	KHALSA J H, BUNT G, BLUM K, et al.. Review: cannabinoids as medicinals[J]. Curr. Addict. Rep., 2022, 9(4): 630-646.

名称	化学式	沸点/℃	闪点/℃	折射率
大麻二酚	C₂₁H₃₀O₂	463.9	206.3	1.545
四氢大麻酚	C₂₁H₃₀O₂	178.6	142.1	1.529
大麻萜酚	C₂₁H₃₂O₂	470.4	207.2	1.536
大麻萜酚酸	C₂₂H₃₂O₄	535.7	291.9	1.555
四氢大麻酚酸	C₂₂H₃₀O₄	436.8	142.1	1.548
四氢大麻素	C₁₉H₂₆O₂	360.0	137.6	1.536

名称	化学式	沸点/℃	闪点/℃	折射率
大麻二酚	C₂₁H₃₀O₂	463.9	206.3	1.545
四氢大麻酚	C₂₁H₃₀O₂	178.6	142.1	1.529
大麻萜酚	C₂₁H₃₂O₂	470.4	207.2	1.536
大麻萜酚酸	C₂₂H₃₂O₄	535.7	291.9	1.555
四氢大麻酚酸	C₂₂H₃₀O₄	436.8	142.1	1.548
四氢大麻素	C₁₉H₂₆O₂	360.0	137.6	1.536

名称	化学式	熔点/℃	沸点/℃	闪点/℃	折射率
山柰酚	C₁₅H₁₀O₆	276	582	226	1.785
芹菜素	C₁₅H₁₀O₅	345	555	217	1.732
槲皮素	C₁₅H₁₀O₇	316	642	248	1.823
木犀草素	C₁₅H₁₀O₆	330	616	239	1.768
牡荆素	C₂₁H₂₀O₁₀	256	767	273	1.743

名称	化学式	熔点/℃	沸点/℃	闪点/℃	折射率
山柰酚	C₁₅H₁₀O₆	276	582	226	1.785
芹菜素	C₁₅H₁₀O₅	345	555	217	1.732
槲皮素	C₁₅H₁₀O₇	316	642	248	1.823
木犀草素	C₁₅H₁₀O₆	330	616	239	1.768
牡荆素	C₂₁H₂₀O₁₀	256	767	273	1.743

工业大麻活性成分及其生理功能研究进展

Research Progress on Active Components and Their Physiological Functions of Industrial Hemp

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 84

相关文章 1

编辑推荐

Metrics

本文评价